BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22552364)

  • 1. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
    Lönnroth C; Andersson M; Nordgren S; Lundholm K
    Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer.
    Lönnroth C; Andersson M; Asting AG; Nordgren S; Lundholm K
    Int J Oncol; 2014 Dec; 45(6):2208-20. PubMed ID: 25340937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.
    Lönnroth C; Andersson M; Arvidsson A; Nordgren S; Brevinge H; Lagerstedt K; Lundholm K
    Cancer Immun; 2008 Feb; 8():5. PubMed ID: 18307280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
    Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
    Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib downregulates CD133 expression through inhibition of the Wnt signaling pathway in colon cancer cells.
    Deng Y; Su Q; Mo J; Fu X; Zhang Y; Lin EH
    Cancer Invest; 2013 Feb; 31(2):97-102. PubMed ID: 23245395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
    Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
    Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
    Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
    Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
    Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
    Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.
    Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T
    Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
    Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
    Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2.
    Gustafsson A; Andersson M; Lagerstedt K; Lönnroth C; Nordgren S; Lundholm K
    Int J Oncol; 2010 Feb; 36(2):469-78. PubMed ID: 20043083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
    Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
    J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
    Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
    Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.
    Huang M; Zhu H; Feng J; Ni S; Huang J
    Dis Markers; 2015; 2015():986095. PubMed ID: 25691807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
    Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
    Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.
    Huang X; Sheng Y; Guan M
    Surg Oncol; 2012 Jun; 21(2):103-7. PubMed ID: 21764578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
    Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
    Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.